MedTrace Logo

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

NCT00506129 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-12-29

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated voluntary donor will help patients with advanced cutaneous T-cell lymphoma. The length of time that patients who receive the treatment remain free of disease will also be studied.

Conditions

  • Lymphoma
  • Disorder Related to Bone Marrow Transplantation

Interventions

DRUG

Fludarabine

25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.

DRUG

Melphalan

70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.

PROCEDURE

Allogeneic Transplant

Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.

DRUG

Thymoglobulin

2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Chitra M. Hosing, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00506129 on ClinicalTrials.gov